Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to shrink tough esophageal tumors

NCT ID NCT07559045

Recruiting now Disease control Sponsor: Second Affiliated Hospital of Zunyi Medical University Source: ClinicalTrials.gov ↗

First seen May 02, 2026 · Last updated May 24, 2026 · Updated 2 times

Summary

This study tests whether giving chemotherapy and immunotherapy before radiation works better than the usual chemoradiation for people with advanced esophageal cancer that cannot be removed by surgery. About 92 adults with stage III–IVA esophageal squamous cell carcinoma will be randomly assigned to one of two treatment plans. The goal is to see which approach leads to more complete tumor shrinkage and longer time without the cancer growing.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Second Affiliated Hospital of Zunyi Medical University, Xinpu New District, Honghuagang District, Zunyi City, Guizhou Province

    RECRUITING

    Zunyi, Guizhou, 563000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)